{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T22:09:23Z","timestamp":1775599763459,"version":"3.50.1"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.parkreldis.2019.05.025","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T12:10:13Z","timestamp":1558613413000},"page":"272-273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["From PARK9 to SPG78: The clinical spectrum of ATP13A2 mutations"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7800-7419","authenticated-orcid":false,"given":"Roberto","family":"Erro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Picillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzo","family":"Manara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Pellecchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-2504","authenticated-orcid":false,"given":"Paolo","family":"Barone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2019.05.025_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11910-018-0847-1","article-title":"Genetics of movement disorders and the practicing clinician; who and what to test for?","volume":"18","author":"Di Fonzo","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.parkreldis.2019.05.025_bib2","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1093\/hmg\/dds089","article-title":"Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis","volume":"21","author":"Bras","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.parkreldis.2019.05.025_bib3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/brain\/aww307","article-title":"Loss-of-function mutations in the ATP13A2\/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78)","volume":"140","author":"Estrada-Cuzcano","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2019.05.025_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10048-010-0259-0","article-title":"Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability","volume":"12","author":"Santoro","year":"2011","journal-title":"Neurogenetics"},{"key":"10.1016\/j.parkreldis.2019.05.025_bib5","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/mds.26243","article-title":"The role of ATP13A2 in Parkinson's disease: clinical phenotypes and molecular mechanisms","volume":"30","author":"Park","year":"2015","journal-title":"Mov. Disord."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019302469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019302469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T11:54:13Z","timestamp":1570794853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802019302469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":5,"alternative-id":["S1353802019302469"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.05.025","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From PARK9 to SPG78: The clinical spectrum of ATP13A2 mutations","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}